Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-01-25 11:32 am Unchanged | 2021-12-31 | 13G | Cogent Biosciences, Inc. COGT | Atlas Venture Fund IX L.P. | 916,196 2.300% | 0 (Unchanged) | Filing History |
| 2021-11-17 3:39 pm Purchase | 2021-11-05 | 13G | Cogent Biosciences, Inc. COGT | TCG Crossover Management LLC | 2,716,042 6.800% | 706,054 (+35.13%) | Filing History |
| 2021-11-03 5:31 pm Purchase | 2021-10-07 | 13G | Cogent Biosciences, Inc. COGT | Commodore Capital LP | 2,141,339 5.400% | 2,141,339 (New Position) | Filing History |
| 2021-07-08 1:50 pm Purchase | 2021-06-28 | 13G | Cogent Biosciences, Inc. COGT | TCG Crossover Management LLC | 2,009,988 5.200% | 2,009,988 (New Position) | Filing History |
| 2021-02-16 4:19 pm Purchase | 2020-12-31 | 13G | Cogent Biosciences, Inc. COGT | Ridgeback Capital Investments L.P. | 1,252,250 5.200% | 1,252,250 (New Position) | Filing History |
| 2021-02-16 3:21 pm Purchase | 2020-12-31 | 13G | Cogent Biosciences, Inc. COGT | Logos Global Master Fund LP | 1,920,500 5.700% | 1,920,500 (New Position) | Filing History |
| 2021-02-12 4:15 pm Purchase | 2020-12-31 | 13G | Cogent Biosciences, Inc. COGT | Ally Bridge MedAlpha Master Fund L.P. | 1,622,591 5.100% | 1,622,591 (New Position) | Filing History |
| 2021-02-12 09:58 am Purchase | 2020-12-31 | 13G | Cogent Biosciences, Inc. COGT | RTW Investments, LP | 1,998,750 3.170% | 740,000 (+58.79%) | Filing History |
| 2021-02-11 4:52 pm Purchase | 2020-12-31 | 13G | Cogent Biosciences, Inc. COGT | BIOTECHNOLOGY VALUE FUND L P | 3,114,250 4.700% | 3,114,250 (New Position) | Filing History |
| 2021-02-02 1:02 pm Purchase | 2020-12-31 | 13G | Cogent Biosciences, Inc. COGT | Atlas Venture Fund IX L.P. | 916,196 8.080% | 916,196 (New Position) | Filing History |
| 2020-12-03 09:29 am Purchase | 2020-11-06 | 13G | Cogent Biosciences, Inc. COGT | RTW Investments, LP | 1,258,750 9.990% | 1,258,750 (New Position) | Filing History |
| 2020-11-19 4:05 pm Purchase | 2020-11-09 | 13G | Cogent Biosciences, Inc. COGT | Logos Global Management LP | 1,907,971 9.990% | 1,907,971 (New Position) | Filing History |
| 2020-11-19 1:55 pm Purchase | 2020-11-09 | 13G | Cogent Biosciences, Inc. COGT | Ally Bridge Group (NY) LLC | 1,420,500 8.030% | 1,420,500 (New Position) | Filing History |
| 2020-09-08 3:10 pm Purchase | 2020-08-27 | 13G | UNUM THERAPEUTICS INC UMRX | Logos Global Management LP | 1,928,291 5.000% | 1,928,291 (New Position) | Filing History |